Rational Design of Novel Peptidomimetics against Influenza A Virus: Biological and Computational Studies.
biophysical assay
docking
hemagglutinin
influenza
peptidomimetic
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
received:
27
07
2023
revised:
08
09
2023
accepted:
15
09
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Effective therapy against the influenza virus is still an unmet goal. Drugs with antiviral effects exist, but the appearance of resistant viruses pushes towards the discovery of drugs with different mechanisms of action. New anti-influenza molecules should target a good candidate, as a new anti-influenza molecule could be an inhibitor of the influenza A virus hemagglutinin (HA), which plays a key role during the early phases of infection. In previous work, we identified two tetrapeptide sequences, SLDC (
Identifiants
pubmed: 37762571
pii: ijms241814268
doi: 10.3390/ijms241814268
pmc: PMC10531517
pii:
doi:
Substances chimiques
Peptidomimetics
0
Hemagglutinins
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
EMBO J. 2014 Apr 16;33(8):823-41
pubmed: 24668228
J Gen Virol. 2023 Apr;104(4):
pubmed: 37018118
J Med Chem. 1997 Jul 4;40(14):2228-40
pubmed: 9216842
ACS Med Chem Lett. 2010 Feb 04;1(1):44-8
pubmed: 24900174
Int J Mol Sci. 2023 Mar 07;24(6):
pubmed: 36982205
Emerg Infect Dis. 2009 Apr;15(4):552-60
pubmed: 19331731
Infect Drug Resist. 2013 Nov 19;6:187-98
pubmed: 24277988
Influenza Other Respir Viruses. 2009 Mar;3(2):69-74
pubmed: 19496844
Lancet. 2013 Jun 29;381(9885):2273-9
pubmed: 23726392
Sci Rep. 2017 Sep 6;7(1):10593
pubmed: 28878220
ACS Polym Au. 2022 Dec 14;2(6):417-429
pubmed: 36536890
Ann Intern Med. 2017 Sep 5;167(5):ITC33-ITC48
pubmed: 28869984
J Med Chem. 1999 Aug 12;42(16):3033-40
pubmed: 10447947
J Biomed Sci. 2019 Oct 23;26(1):84
pubmed: 31640786
Cochrane Database Syst Rev. 2014 Nov 21;(11):CD002745
pubmed: 25415374
J Virol Methods. 1998 Sep;74(1):57-66
pubmed: 9763129
Pathog Glob Health. 2012 Mar;106(1):12-9
pubmed: 22595270
Cell. 2009 Feb 6;136(3):402-10
pubmed: 19203576
Clin Infect Dis. 2018 Feb 1;66(4):533-540
pubmed: 29401271
Curr Opin Virol. 2014 Oct;8:22-9
pubmed: 24866471
J Med Chem. 1992 May 29;35(11):2040-8
pubmed: 1597855
Antiviral Res. 2007 Mar;73(3):228-31
pubmed: 17112602
J Med Chem. 2009 Aug 27;52(16):5197-206
pubmed: 20560644
Int J Mol Sci. 2022 Sep 28;23(19):
pubmed: 36232735
Acta Biochim Pol. 2014;61(3):495-504
pubmed: 25180220
J Med Chem. 2001 Apr 12;44(8):1305-11
pubmed: 11312929
Appl Microbiol. 1968 Apr;16(4):588-94
pubmed: 5647517
Bioorg Med Chem Lett. 2008 Jan 1;18(1):60-5
pubmed: 18060774
J Med Chem. 1993 Feb 5;36(3):363-9
pubmed: 8381183
Infect Drug Resist. 2017 Apr 20;10:121-134
pubmed: 28458567
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9367-71
pubmed: 1409642
J Antibiot (Tokyo). 1997 Sep;50(9):734-7
pubmed: 9360617
Antiviral Res. 2011 Oct;92(1):7-14
pubmed: 21513746
Biophys J. 2007 Nov 1;93(9):3015-25
pubmed: 17631541
J Med Chem. 1991 Oct;34(10):3114-25
pubmed: 1920361
Pharmaceuticals (Basel). 2021 Sep 23;14(10):
pubmed: 34681184
Proc Natl Acad Sci U S A. 1985 Nov;82(21):7444-8
pubmed: 2414777
Curr Opin Infect Dis. 2006 Apr;19(2):169-78
pubmed: 16514342
Curr Opin Mol Ther. 2009 Jun;11(3):299-307
pubmed: 19479663
N Engl J Med. 2005 Sep 29;353(13):1374-85
pubmed: 16192482
Curr Drug Targets. 2003 Jul;4(5):389-408
pubmed: 12816348